Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Indaptus Therapeutics, Inc. (INDP : NSDQ)

• Company Description    Indaptus Therapeutics approach is based on the hypothesis which efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals. Indaptus Therapeutics, formerly known as Intec Parent Inc., is based in NEW YORK. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $3.16 Daily Weekly Monthly 20 Day Moving Average: 492,427 shares Shares Outstanding: 133.24 (millions) Market Capitalization: $421.05 (millions) Beta: 0.97 52 Week High: $5.96 52 Week Low: $0.92 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.18% -16.73% 12 Week 73.63% 63.76% Year To Date 8.59% -4.17%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3 COLUMBUS CIRCLE 15TH FLOOR - NEW YORK,NY 10019 USA ph: 646-427-2727 fax: 972-2586-9176 investors@indaptusrx.com https://indaptusrx.com

• General Corporate Information    Officers David E. Lazar - Co-Chief Executive Officer and Chairman Jeffrey A. Meckler - Co-Chief Executive Officer and Director Nir Sassi - Chief Financial Officer David Natan - Director Roger J. Pomerantz - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45339J204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 133.24 Most Recent Split Date: 6.00 (0.04:1) Beta: 0.97 Market Capitalization: $421.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 31.47 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 99.78% vs. Previous Quarter: 91.30% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -302.89 03/31/26 - -1,030.07 ROA 09/30/26 - - 06/30/26 - -203.49 03/31/26 - -299.69 Current Ratio 09/30/26 - - 06/30/26 - 19.49 03/31/26 - 2.34 Quick Ratio 09/30/26 - - 06/30/26 - 19.49 03/31/26 - 2.34 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 0.10 03/31/26 - 0.01 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©